tradingkey.logo
tradingkey.logo
검색

Quantum BioPharma Ltd

QNTM
관심 목록에 추가
3.510USD
+0.150+4.46%
종가 07/02, 13:00ET시세는 15분 지연됩니다
20.55M시가총액
손실P/E TTM

Quantum BioPharma Ltd

3.510
+0.150+4.46%

자세한 내용은 Quantum BioPharma Ltd 회사

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Quantum BioPharma Ltd 정보

종목 코드 QNTM
회사 이름Quantum Biopharma Ltd
상장일May 29, 2018
CEOKotra (Lakshmi P)
직원 수- -
유형Ordinary Share
회계 연도 종료May 29
주소55 University Ave. , Suite 1003
도시TORONTO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Canada
우편 번호M5J 2H7
전화14168548884
웹사이트https://www.quantumbiopharma.com/
종목 코드 QNTM
상장일May 29, 2018
CEOKotra (Lakshmi P)

Quantum BioPharma Ltd의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
348.02K
+32.99%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
258.72K
+44.37%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
114.81K
-100.00%
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Dr. Eric Hoskins, M.D.
Dr. Eric Hoskins, M.D.
Independent Director
Independent Director
--
--
Mr. Michael (Zappy) Zapolin
Mr. Michael (Zappy) Zapolin
Independent Director
Independent Director
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-100.00%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
348.02K
+32.99%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
258.72K
+44.37%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
114.81K
-100.00%
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--

자주 묻는 질문

Quantum BioPharma Ltd의 상위 5대 주주는 누구인가요?

Quantum BioPharma Ltd의 상위 5대 주주는 다음과 같습니다: Mr. Zeeshan Saeed

Quantum BioPharma Ltd(QNTM)의 주식을 보유한 기관은 몇 개입니까?

2026Q1 기준으로, Quantum BioPharma Ltd의 주식을 보유한 기관은 총 44곳이며, 이들이 보유한 주식의 총 가치는 약 568.64K로 전체 발행 주식의 8.89%를 차지합니다. 이는 2025Q4 대비 -641837.00 증가한 수치입니다.